503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Record LWR-ST-09 · South Region CERN/Zenodo DOI: 10.5281/zenodo.24139340 View Full 51-Jurisdiction Dataset →

District of Columbia (DC) GLP-1 Telehealth Access, Medicaid Coverage & Clinic Cost Audit (2026)

Empirical regulatory and out-of-pocket pricing benchmark for District of Columbia residents evaluating Semaglutide and Tirzepatide in 2026. In-person District of Columbia weight loss clinics average $590/mo (Semaglutide) and $810/mo (Tirzepatide), compared to verified flat-rate telehealth programs at $49/mo and $99/mo across all dosage tiers.

DC Local Med-Spa Median
$590/mo Sema
$810/mo local Tirzepatide median
Annual Flat-Rate Savings
$6,492/yr
$8,532/yr saved on Tirzepatide ($99/mo flat)
Commercial PA Denial Rate
37.9%
Adult obesity prevalence: 24.7%
DC Access Equity Score
94/100
2-day cold-chain pharmacy transit

2026 District of Columbia Telehealth & Coverage Matrix

Regulatory / Economic Dimension District of Columbia (DC) Verified Status Patient Impact
Initial Telehealth Exam Rule Asynchronous Clinical Questionnaire Permitted Eligible patients can complete intake online at any hour for clinician review.
Adult Medicaid Obesity GLP-1 Coverage Covered (Strict PA & Step Therapy) Requires documented BMI & prior-authorization approval.
State Employee Health Plan GLP-1 Active Benefit Pathway Subject to plan-specific utilization management.
503A Sterile Pharmacy Licensing Tier Standard NABP Verified Non-Resident Pharmacy Reciprocity Cold-chain express delivery in ~2 business days statewide.
Semaglutide 12-Month Out-of-Pocket Local Clinic: $7,080/yr vs. Online Flat: $588/yr Saves $6,492/year ($0 monthly membership fee).
Tirzepatide 12-Month Out-of-Pocket Local Clinic: $9,720/yr vs. Online Flat: $1,188/yr Saves $8,532/year across 2.5 mg–15 mg tiers.

Primary Data Citation: Losing Weight RX Pharmacoeconomics & Consumer Audit Desk (2026). U.S. 50-State + D.C. Telehealth GLP-1 Prescribing Modality, Medicaid Coverage & Access Equity Matrix. DOI: 10.5281/zenodo.24139340 · State Reference: KFF DC State Health Facts.

Audited Metro Weight Loss Markets in District of Columbia (1 City)

Compare bricks-and-mortar bariatric clinic consultation fees and med-spa vial markups in District of Columbia's major metropolitan areas against flat-rate national telehealth delivery:

Washington, D.C., DC Clinic Cost Audit →

Interactive District of Columbia GLP-1 Household Savings Estimator

Select your medication and treatment horizon to compare District of Columbia local clinic pricing against flat-rate online delivery:

Estimated DC Savings
$6,492
Local: $7,080 vs Flat Online: $588

Frequently Asked Questions — District of Columbia (DC)

Does District of Columbia Medicaid cover GLP-1 medications for adult weight loss in 2026?

Yes. As of November 2026, District of Columbia (DC) fee-for-service Medicaid maintains an active adult obesity GLP-1 pathway subject to strict prior authorization, BMI thresholds, and step-therapy documentation. Patients who do not qualify for Medicaid or face commercial prior-authorization denials (37.9% estimated initial denial rate in District of Columbia) frequently use self-pay flat-rate telehealth options starting at $49/mo for Semaglutide and $99/mo for Tirzepatide.

Is an online questionnaire allowed for GLP-1 telehealth prescriptions in District of Columbia?

Yes. District of Columbia telehealth regulations permit asynchronous clinical questionnaire permitted when reviewed by a District of Columbia-licensed clinician who determines clinical eligibility, contraindications, and appropriate starting titration.

How much do local weight loss clinics in District of Columbia charge compared to online flat-rate care?

Across District of Columbia, local in-person med-spas and cash bariatric clinics charge a median of $590/month for compounded Semaglutide and $810/month for compounded Tirzepatide. Switching to verified flat-rate online care ($49/mo Semaglutide, $99/mo Tirzepatide across all doses) saves District of Columbia households an estimated $6,492/year on Semaglutide or $8,532/year on Tirzepatide.

Insurance PA Denial vs. Cash-Pay Calculator → 52-Week Dose-Titration Cost Calculator → Read Full 50-State Empirical Study → Compare Online Providers →

Clinical & Regulatory References

The clinical efficacy, safety, and District Of Columbia telehealth regulatory information in District of Columbia (DC) GLP-1 Telehealth Access, Medicaid Coverage & Clinic Cost Audit (2026) is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Capehorn, M., Johansson, E., Davies, A., Evans, J., Godbeer, F., van Hest, N., Cotterill, G., & Tolley, K. (2025). Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective. Advances in therapy, 42(10), 5055-5071. https://doi.org/10.1007/s12325-025-03288-3
  2. DC Health. (2025). Public health, chronic disease, and clinical telehealth resources. https://dchealth.dc.gov/
  3. Kim, N., Wang, J., Burudpakdee, C., Song, Y., Ramasamy, A., Xie, Y., Sun, R., Kumar, N., Wu, E. Q., & Sullivan, S. D. (2022). Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. Journal of managed care & specialty pharmacy, 28(7), 740-752. https://doi.org/10.18553/jmcp.2022.28.7.740
  4. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  5. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know
  6. Wang, S., Fan, D., Yao, Q., & Sun, X. (2025). The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China. Diabetes, obesity & metabolism, 27(9), 5269-5279. https://doi.org/10.1111/dom.16580